

March 19, 2018

*CLLPAG posts information about specific drugs once they are approved for inclusion in a provincial formulary. However, there has been a lot of interest in the Venetoclax decision and we are posting the following update that was provided by AbbVie.*

On March 2, pCODR issued to the provinces (except Quebec) a conditional positive reimbursement recommendation for Venclexta provided that the cost-effectiveness is improved via a substantial price reduction until more robust data is available for a future reassessment.

The provincial approval process has begun in Ontario.

“On February 1, INESSS published a negative Venclexta recommendation to the Ministry of Health. As a result, Venclexta will not be listed on the Quebec formulary for now. In the meantime, it is important to remember that a coverage request for Venclexta can be submitted to the [Patient d’exception](#) program.

Canadians prescribed VENCLEXTA will have the opportunity to be enrolled in [AbbVie Care](#). The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment and beyond.